ACTRN12607000421437已完成3 期
A three-month, double-blind, parallel-group, placebo-controlled randomized clinical trial to investigate the remineralizing capacity of casein phosphopeptide-amorphous calcium phosphate in a post-orthodontic population.
GC Corporation0 个研究点目标入组 46 人开始时间: 2007年8月21日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 12 Years 至 18 Years（—）
- 性别
- All
入选标准
- •Undergoing fixed orthodontic treatment and due to have appliances removed during study period.
- •Exhibiting a minimum of two WSLs on the buccal surfaces of teeth 14 to 44 (or 15 to 45 when first premolars have been extracted) at time of recruitment.
- •Able to attend for four visits over a 12 week period.
排除标准
- •a.Allergies to milk proteins.
- •b.Ulcerative mucosal conditions.
- •c.Chronic use of medication causing xerostomia.
- •d.Allergies to preservatives (or other ingredients) present in Tooth Mousse or placebo.
- •e.Unrestored dentinal caries in teeth 14 to 44 (or 15 to 45).
- •f.Pregnancy.
- •g.Any other illnesses/conditions that the Investigator deems could affect the study outcome.
研究者
相似试验
进行中（未招募）
不适用
A three months, double-blind, randomized, parallell-group study evaluating the efficacy of sitagliptin (Januvia®) versus placebo on beta-cell function in patients with newly detected glucose abnormalities and acute myocardial infarction or unstable angina - BEGAMIEUCTR2007-003963-31-SEKarolinska Institutet70
进行中（未招募）
1 期
A three-month, double-blind, double dummy, parallel group, controlled study comparing the efficacy and safety between 12 µg twice daily of Formoterol-HFA and 12 µg twice daily of Formoterol-DPI (Foradil/Aerolizer) in children with persistent asthmaChildren Persistent AsthmaMedDRA version: 7.0Level: LowClassification code 10003553EUCTR2004-000755-41-CZChiesi Farmaceurtici S.p.A460
进行中（未招募）
不适用
A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole NexiumTR 40 mg twice daily or 40 mg once daily with placebo in adults with asthma - RELAX STUDYSub-optimally controlled moderate to severe asthma and symptoms of GERD.MedDRA version: 6.1Level: PTClassification code 10003553EUCTR2005-004543-57-ITASTRAZENECA1,015
进行中（未招募）
不适用
A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole (Nexium) 40 mg twice daily or 40 mg once daily with placebo in adults with asthma - NAEUCTR2005-004543-57-CZAstraZeneca AB1,100
进行中（未招募）
不适用
A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole (Nexium) 40 mg twice daily or 40 mg once daily with placebo in adults with asthma - NAModerate to severe asthma and symptoms of gastroesophageal reflux disease (GERD)EUCTR2005-004543-57-DEAstraZeneca AB1,100